

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2023

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) is pleased to announce the poll results of the first extraordinary general meeting of 2023 (the “**EGM**”) held on November 16, 2023.

For details of the resolution considered at the EGM, the shareholders of the Company (the “**Shareholders**”) may refer to the relevant notice of the EGM and the Company’s circular dated October 27, 2023 (the “**Circular**”).

CONVENING AND ATTENDANCE OF THE EGM

The EGM was held as an on-site meeting at 2:00 p.m. on Thursday, November 16, 2023, at Conference Room 210, 2nd Floor, Building C2-1, No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Wuhan, Hubei Province, PRC.

The EGM was convened by the Board and hosted by Dr. Zhou Pengfei, the chairman of the Board. All the directors of the Company (the “**Directors**”) attended the EGM, either in person or online.

The convention of the EGM was in compliance with the requirements of the applicable PRC laws and regulations, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company (the “**Articles of Association**”). The resolution set out in the Circular was tabled before the EGM for Shareholders’ consideration and approval, and was put to vote by way of poll.

To the best knowledge of the Board, having made reasonable inquiries (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the EGM; (ii) no Shareholder has a material interest in the matter considered at the EGM and was required to abstain from voting at the EGM; (iii) there were no shares of the Company (the “**Shares**”) entitling the holders to attend and abstain from voting in favor of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the EGM.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolution proposed at the EGM was 193,849,200, including 82,380,386 unlisted Shares and 111,468,814 H Shares. Shareholders and authorized proxies holding an aggregate of 175,287,687 Shares attended the EGM, representing approximately 90.42% of the total number of Shares with voting rights.

At the EGM, the following resolution was considered and passed by registered poll and the poll results are set out as follows:

Special Resolution		Number of Votes (%)		
		For	Against	Abstain
1.	Amendments to the Articles of Association.	175,287,687 (100.00%)	0 (0.00%)	0 (0.00%)

As more than two-thirds of the votes were cast in favor of the above special resolution, the special resolution was duly passed.

SCRUTINEERS

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two Shareholders' representatives, the supervisor of the Company, Mr. Zhang Jing and a lawyer from Beijing Dentons Law Offices, LLP (WUHAN), the PRC legal adviser of the Company, Mr. Hua Hao served as the scrutineers of the EGM for the purpose of vote-taking.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Wuhan, PRC, November 16, 2023

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Liu Dan, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.